SUPPLEMENTARY FIGURES AND TABLES

Supplementary Figure S1. Injection site reaction in patient M21.

Supplementary Figure S2. Humoral immune responses to NY-ESO-1 protein and peptides in individual patients throughout vaccination with NY-ESO-1 OLP. A) Reciprocal titers of plasma IgG antibodies were measured throughout vaccination by ELISA against NY-ESO-1 recombinant protein. Each patient was tested for all available time points, from prestudy (pre) up to week (w) 16. B) IgG plasma antibody responses were analyzed using 20-mer OLP in ELISA from samples at the time points where maximal titers had been achieved against NY-ESO-1 protein following vaccination. Peaks represent titers against 20-mer individual peptides centered around amino-acids from NY-ESO-1 shown along the X-axis. Reciprocal titers were considered significant if > 100. Assays representative of at least 2 repeats.

Supplementary Figure S3. Detection of NY-ESO-1-specific CD4\(^+\) T cells by intracellular cytokine staining. CD4\(^+\) T cells were stimulated once with T-cell depleted PBMC pulsed with NY-ESO-1 assay OLP and after 22-23 day culture, NY-ESO-1-specific IFN-\(\gamma\) and IL-5 production was evaluated by intracellular cytokine staining. Peptide-pulsed or unpulsed autologous EBV-B cells pulsed or unpulsed with 20-mer NY-ESO-1 peptides covering areas indicated were used as target cells. Responses shown at week 16 after vaccination in two patients (M09 and M19) representative of Cohort 2 and 3, respectively.

Supplementary Table S1: Immunohistochemical analysis of NY-ESO-1 expression (mAb E978) in tumor tissue and vaccine regimen.

Supplementary Table S2: Incidence of treatment-related adverse events by maximum grade.